ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
62,994.22
-0.60%
S&P 500
5,702.55
-0.19%
Dow Jones
42,063.36
0.09%
US Dollar vs Yen
143.825
0.00%
Brent Oil
74.135
0.00%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. NeuroSense Therapeutics Ltd (NRSN)

  7. NeuroSense Therapeutics Ltd (NRSN) ニュース

NRSN

NeuroSense Therapeutics (NRSN)

NeuroSense Therapeutics Ltd
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:NRSN
日付受信時刻ニュースソース見出しコード企業名
2024/08/3106 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/08/3105 : 30PR Newswire (US)NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/08/2820 : 05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/08/2621 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/08/1705 : 06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/08/1705 : 05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/08/0803 : 00PR Newswire (US)NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market PriceNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/08/0722 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/08/0122 : 24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/08/0122 : 15PR Newswire (US)NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/07/0922 : 27PR Newswire (US)NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease ProgressionNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/07/0121 : 00PR Newswire (US)NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying DrugNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/06/2422 : 00PR Newswire (US)NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial ResultsNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/06/2205 : 30PR Newswire (US)NeuroSense Receives Delisting Notice from Nasdaq and Intends to AppealNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/05/2022 : 00PR Newswire (US)NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/05/1422 : 05PR Newswire (US)NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/05/0721 : 45PR Newswire (US)NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/05/0222 : 19PR Newswire (US)NeuroSense Announces First Quarter 2024 Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/04/2221 : 30PR Newswire (US)NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/04/1821 : 30PR Newswire (US)NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/04/1221 : 30PR Newswire (US)NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024NASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/04/1108 : 16PR Newswire (US)NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/04/0921 : 30PR Newswire (US)NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/04/0522 : 29PR Newswire (US)NeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/02/2222 : 25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/02/2222 : 25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/02/2122 : 30PR Newswire (US)NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/02/1403 : 20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/02/1400 : 14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRSNNeuroSense Therapeutics Ltd
2024/02/0723 : 38Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:NRSN

最近閲覧した銘柄

COIN
SOLUSD
Solana
NASDAQ
GOOGL
Alphabet
COIN
BTCUSD
Bitcoin
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
KO
Coca Cola
FX
USDJPY
US Dollar vs Yen
CCOM
SILVER
SILVER
NYSE
MCD
McDonalds
PM
XAUUSD
Gold vs US Dollar
NYSE
DIS
Walt Disney
NYSE
BAC
Bank of America
NYSE
AXP
American Express
CCOM
US500
US 500
NYSE
MRK
Merck
NYSE
VZ
Verizon Communications
USOTC
RHHBY
Roche (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有